GLPwatch

A Targeted RNAi Screen Identifies Endocytic Trafficking Factors That Control GLP-1 Receptor Signaling in Pancreatic β-Cells.

Diabetes · 2018

Last updated 2026-05-28

Researchers studied how the GLP-1 receptor, which helps control blood sugar, works in insulin-producing cells. They tested 29 proteins involved in cell transport and found that 5 increased insulin secretion while 4 decreased it when exposed to a GLP-1 drug called exendin-4. Two specific proteins, SNX1 and SNX27, were shown to influence how the receptor recycles or breaks down, affecting the cell's response to the drug.

AI summary of the abstract below.

JournalDiabetes, 2018
Citations33
Relative citation ratio1.28
NIH percentile59
Molecules
Conditions studied Type 2 Diabetes

Abstract

The glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) is a key target for type 2 diabetes (T2D) treatment. Because endocytic trafficking of agonist-bound receptors is one of the most important routes for regulation of receptor signaling, a better understanding of this process may facilitate the development of new T2D therapeutic strategies. Here, we screened 29 proteins with known functions in G protein-coupled receptor trafficking for their role in GLP-1R potentiation of insulin secretion in pancreatic β-cells. We identify five (clathrin, dynamin1, AP2, sorting nexins [SNX] SNX27, and SNX1) that increase and four (huntingtin-interacting protein 1 [HIP1], HIP14, GASP-1, and Nedd4) that decrease insulin secretion from murine insulinoma MIN6B1 cells in response to the GLP-1 analog exendin-4. The roles of HIP1 and the endosomal SNX1 and SNX27 were further characterized in mouse and human β-cell lines and human islets. While HIP1 was required for the coupling of cell surface GLP-1R activation with clathrin-dependent endocytosis, the SNXs were found to control the balance between GLP-1R plasma membrane recycling and lysosomal degradation and, in doing so, determine the overall β-cell incretin responses. We thus identify key modulators of GLP-1R trafficking and signaling that might provide novel targets to enhance insulin secretion in T2D.

Verbatim abstract via PubMed 29284659 ↗